Nvidia's landmark plan to invest up to $100 billion in OpenAI has stalled, with executives questioning the deal's structure and OpenAI's financial discipline amid a fiercely competitive AI landscape.
The family of Milagros Ortiz demands accountability after a marked police cruiser, found at fault in a preliminary report, struck her car, leading to her death. An internal investigation is ongoing.
The Geely-owned electric vehicle maker Polestar has secured a major $400 million equity investment from a consortium led by Sumitomo Mitsui Banking Corporation and Standard Chartered Bank, signaling crucial financial backing as it navigates a competitive market.
A partial government shutdown triggers furloughs, the Grammys become a platform for political statements, and nationwide protests over immigration policy unfold amid a severe winter storm's aftermath.
The European Commission has granted regulatory approval, concluding the acquisition of iconic Italian motorsports brand Dainese by asset management firms Arcmont and HPS Investment Partners, effectively placing ownership under major institutional investors.
The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Foundation Investment Partners, through its platform Sustainable Packaging, has acquired Paper Converters, a Walterboro-based manufacturer of spiral-wound paper tubes and boards, marking a strategic consolidation in the eco-friendly packaging sector.
Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.
The European CE Mark under the stringent MDR has been granted for Cynosure Lutronic's innovative fractional resurfacing system, designed to improve safety and patient comfort through advanced cooling and precision technology.
While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Amidst a cautiously optimistic economic backdrop in Europe, we examine three publicly traded companies with market capitalizations exceeding €30 million that combine the growth potential of small-caps with notable financial resilience.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
A syndicate led by JPMorgan and Wells Fargo is preparing a multi-billion dollar high-yield bond and loan issuance to finance the landmark private equity acquisition of Bubble Wrap maker Sealed Air, with bond yields expected to attract investor interest in the 7% range.
The Rafah border crossing between Gaza and Egypt partially reopened Monday under European Union operation, permitting restricted passage for Palestinians after a near two-year Israeli closure. The move is part of a U.S.-brokered ceasefire agreement, though high costs and tight quotas severely limit access.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
A coalition of major international NGOs is refusing to comply with Israeli orders to hand over detailed staff information, calling it a safety risk and an obstruction of aid, as tensions escalate following the expulsion of Médecins Sans Frontières.
